Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02943317 · ClinicalTrials.gov registry record · Phase 1
Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer
A Phase 1 study, sponsored by Verastem.
- Terminated
- Registry status
- Phase 1
- Development phase
- 98
- Enrollment target
NCT02943317: Clinical Trial Phase 1 study, sponsored by Verastem.
NCT02943317 is a Phase 1 study that was terminated before completion, run by Verastem. The registered enrollment target is 98 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02943317, a Phase 1 study, was terminated before completion, sponsored by Verastem.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 98 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.
Interventions
- DRUG Part A - VS-6063
- DRUG Part A - Avelumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 98 participants |
| Start Date | 2016-10 |
| Est. Completion | 2018-12-28 |
| Phase | Phase 1 |
Why NCT02943317 stopped before completion
NCT02943317 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 98 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% higher).
The record links to 0 conditions, and to 2 interventions - of which Part A - VS-6063 is the first listed.
NCT02943317 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02943317 about?
NCT02943317 is a clinical study titled "Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer". This is a Phase 1/1b, open-label, multicenter, dose-escalation and dose expansion trial to evaluate the safety, efficacy, PK and PD of defactinib (VS-6063) in combination with avelumab in epithelial ovarian cancer.
What is the current status of trial NCT02943317?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 98 participants. The study started on 2016-10. Estimated completion is 2018-12-28.
What interventions are being tested in trial NCT02943317?
The interventions under investigation include: Part A - VS-6063 (DRUG), Part A - Avelumab (DRUG).
Who is sponsoring clinical trial NCT02943317?
This trial is sponsored by Verastem, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02943317's enrollment target sits among peer trials
98 592nd of 2000 higher than 1,404 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02926729 · 98 participants · NA
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
- NCT03382977 · 98 participants · Phase 1
Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects
- NCT04577014 · 98 participants · Phase 1
Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma
- NCT04817618 · 98 participants · Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia